Enpp-1-IN-1
(Synonyms: N-4-(7-Methoxyquinolin-4-yl)benzylsulfamide, MV 658, UUN28589) 目录号 : GC38775
一键复制产品信息
Enpp-1-IN-1是一种有效的选择性Ectonucleotide pyrophosphatase-phosphodiesterase 1（enpp-1）抑制剂。
Cas No.:2289728-58-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Enpp-1-IN-1 is a potent and selective ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitor[1-2]. Enpp-1-IN-1 is primarily employed in research to explore tumor immunotherapy[3].
In vitro, treatment of various RAS-mutant cancer cell lines (such as A549, H460, and H2030) with Enpp-1-IN-1 (11 or 33μM) for 72–96 hours significantly inhibits cell viability and proliferation[4]. Treating peripheral blood mononuclear cells (PBMCs) derived from small cell lung cancer (SCLC) patients with Enpp-1-IN-1 (2μM) for 72 hours significantly upregulates the mRNA expression levels of STING, MAVS, and IFI16[6].
References:
[1] Ji H, Jiang W, Zhang J, et al. ENPP1 governs the metabolic regulation of effector T cells in autoimmunity by detecting cytosolic mitochondrial DNA. Cell Rep. 2025 Jun 24;44(6):115851.
[2] Liu Q, Wang R, Hou S, et al. Chondrocyte-derived exosomes promote cartilage calcification in temporomandibular joint osteoarthritis. Arthritis Res Ther. 2022 Feb 14;24(1):44.
[3] Ng DYX, Li Z, Lee E, et al. Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor. NPJ Breast Cancer. 2022 Apr 1;8(1):44.
[4] Xia RX, Zou PC, Xie JT, et al. Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers. Acta Pharmacol Sin. 2025 Mar;46(3):728-739. doi: 10.1038/s41401-024-01409-2.
[5] De Rosa C, Morgillo F, Amato L, et al. DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer. iScience. 2025 Feb 1;28(3):111943.
Enpp-1-IN-1是一种有效的选择性Ectonucleotide pyrophosphatase-phosphodiesterase 1（enpp-1）抑制剂[1-2]。Enpp-1-IN-1主要被运用于探索肿瘤免疫治疗的相关研究[3]。
在体外，Enpp-1-IN-1（11–33μM）处理多种RAS突变癌细胞（如A549、H460、H2030等）72–96小时，可显著抑制细胞活力与增殖[4]。Enpp-1-IN-1（2μM）处理小细胞肺癌（SCLC）患者来源的外周血单个核细胞（PBMCs）72小时，Enpp-1-IN-1可显著上调STING、MAVS和IFI16的mRNA表达水平[5]。
| Cell experiment [1]: | |
|
Cell lines |
A panel of human cancer cell lines (including A549, H460, HCT116, SW480, etc.) and normal lung epithelial cells (BEAS-2B) |
|
Preparation Method |
Cells were propagated in respective media (DMEM, F-12K, McCoy’s 5a, or RPMI-1640) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C, 5% CO₂. Cells were treated with Enpp-1-IN-1 at 11μM or 33μM for 72–96 hours. |
|
Reaction Conditions |
11μM or 33μM for 72–96h |
|
Applications |
Enpp-1-IN-1 selectively suppressed viability and growth of RAS-mutant cancer cells while exhibiting minimal effects on normal cells (BEAS-2B) or RAS-wildtype cells (HCC827). Enpp-1-IN-1 impaired hexokinase activity by disrupting the NPPS-HK1 interaction, leading to reduced glycolysis and accumulation of glucose-6-phosphate. |
|
References: |
|
| Cas No. | 2289728-58-9 | SDF | |
| 别名 | N-4-(7-Methoxyquinolin-4-yl)benzylsulfamide, MV 658, UUN28589 | ||
| Canonical SMILES | O=S(N)(NCC1=CC=C(C2=CC=NC3=CC(OC)=CC=C23)C=C1)=O | ||
| 分子式 | C17H17N3O3S | 分子量 | 343.4 |
| 溶解度 | DMSO: 250 mg/mL (728.01 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9121 mL | 14.5603 mL | 29.1206 mL |
| 5 mM | 582.4 μL | 2.9121 mL | 5.8241 mL |
| 10 mM | 291.2 μL | 1.456 mL | 2.9121 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet